Skip to main content

Advertisement

Table 3 Model parameter estimates and data sources

From: The present and future burden of previously treated advanced non-small cell lung cancer (NSCLC) by histology and line of therapy in France, Germany, Italy, and Spain: model-based predictions

Parameter France Germany Italy Spain Model code color
Proportion non-small cell cases at diagnosis (%) 83.1 81.2 84.8 86.6 Orange
  Source [34] [35] [32] [36]
Squamous (%)   38.3 35.9 32.2 40.5
Non-squamous (%)   61.7 64.1 67.8 59.5
Source [12, 13] [12, 13] [32] [12, 13]
Stage at diagnosis (%) I 7.5 13.7 10.0 7.4 Purple
II 7.9 8.3 5.9 6.2
III 25.2 33.4 23.3 33.4
Proportion of stage III patients who are IIIb (%) 49.6 60.8 63.1 68.3
  IV 52.9 41.3 53.5 48.5
Unknown 6.5 3.3 7.3 4.5
Source [37]
Five-year rate of distant recurrence of the tumor from stage (%) I 25.8 Blue
II 45.8
IIIa 44.8
Source [38]
Median OS (months) Squamous NSCLC 6.0
Source [10]
Non-squamous NSCLC 9.4
Source [11]
Proportion of advanced NSCLC patients referred to BSC (%) 11.7% Aqua blue
Proportion eligible for systemic treatment (%) 88.3%
  Source [36]
Proportion of squamous patients receiving (%) First LOT 77.9 89.2 90.0 97.5 Green
Second LOT 28.6 37.8 42.2 39.2
Third LOT 10.4 9.5 10.0 2.5
Proportion of non-squamous patients receiving (%) First LOT 89.5 93.8 92.3 99.1
Second LOT 46.8 52.3 57.7 54.3
Third LOT 12.9 18.5 8.7 16.4
Source [13]